Immune-Targeted Therapies for Depression: Current Evidence for Antidepressant Effects of Monoclonal Antibodies.

Autor:	Rizk MM; Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, New York.; Molecular Imaging and Neuropathology Division, New York State Psychiatric Institute, New York.; Corresponding Author: Mina M. Rizk, MD, Department of Psychiatry, Icahn School of Medicine at Mount Sinai, 1 Gustave Levy Place, Box #1230, New York, NY 10029 (mina.rizk@mountsinai.org)., Bolton L; Molecular Imaging and Neuropathology Division, New York State Psychiatric Institute, New York., Cathomas F; Nash Family Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, New York.; Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, New York., He H; Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York., Russo SJ; Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, New York.; Nash Family Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, New York.; Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, New York., Guttman-Yassky E; Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York., Mann JJ; Molecular Imaging and Neuropathology Division, New York State Psychiatric Institute, New York.; Department of Psychiatry, Columbia University Irving Medical Center, New York, New York.; Department of Radiology, Columbia University Irving Medical Center, New York, New York., Murrough J; Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, New York.; Nash Family Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, New York.; Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
Jazyk:	angličtina
Zdroj:	The Journal of clinical psychiatry [J Clin Psychiatry] 2024 Jun 24; Vol. 85 (3). Date of Electronic Publication: 2024 Jun 24.
DOI:	10.4088/JCP.23nr15243
Abstrakt:	Importance: Increasing evidence suggests a potential role of immune-modulatory drugs for treatment-resistant depression. This scoping review explores the emerging evidence regarding the antidepressant effects of monoclonal antibodies (mAbs), a relatively newer class of immune therapeutics with favorable safety profile. Observations: PubMed was searched up to November 2023 for English publications addressing the antidepressant effects of mAbs, including meta-analyses, randomized controlled trials, open-label, single-arm studies, and case series. Several mAbs have shown potential antidepressant effects, but most studies in primary inflammatory disorders included patients with mild depression. Only infliximab and sirukumab were directly examined in individuals with primary depression. mAbs that do not require laboratory monitoring, such as ixekizumab and dupilumab, could hold potential promise if future studies establish their safety profile regarding suicide risk. Conclusions and Relevance: The use of several mAbs for the treatment of primary inflammatory disorders has been associated with improvement of comorbid depressive symptoms. Given their unique mechanisms of action, mAbs may offer a new hope for depressed patients who do not respond to currently available antidepressants. Further research addressing individuals with more severe depressive symptoms is essential. Direct examination of antidepressant effects of mAbs in people with primary depressive disorders is also crucial to refine their clinical use in the treatment of depression. (© Copyright 2024 Physicians Postgraduate Press, Inc.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu